Nifty
:
17274.30
Sensex
:
58065.47
386.95 (2.29%)
1276.66 (2.25%)
Nifty
Sensex
:
:
17274.30
58065.47
386.95 (2.29%)
1276.66 (2.25%)

Natco Pharma Ltd.

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 524816 | NSE: NATCOPHARM

NSE BSE
624.45
04-Oct-2022
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 614.80
  • 627.00
  • 613.50
  • 611.60
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  285961
  •  1774.39
  •  944.00
  •  592.45

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 11,181.63
  • 26.78
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 11,379.53
  • 0.73%
  • 2.43

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 48.80%
  • 4.46%
  • 18.45%
  • FII
  • DII
  • Others
  • 11.65%
  • 14.23%
  • 2.41%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.40
  • -2.30
  • 0.52

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.80
  • -22.27
  • -14.67

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.99
  • -24.57
  • -28.28

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 37.36
  • 27.27
  • 36.83

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.35
  • 3.96
  • 3.54

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.04
  • 19.96
  • 23.54

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Dec 21
Dec 20
Var%
Sep 21
Sep 20
Var%
Net Sales
884.60
410.30
115.60%
596.80
331.30
80.14%
560.50
355.20
57.80%
377.20
802.20
-52.98%
Expenses
489.30
300.50
62.83%
615.40
255.10
141.24%
458.70
272.70
68.21%
306.70
525.80
-41.67%
EBITDA
395.30
109.80
260.02%
-18.60
76.20
-
101.80
82.50
23.39%
70.50
276.40
-74.49%
EBIDTM
44.69%
26.76%
-3.12%
23.00%
18.16%
23.23%
18.69%
34.46%
Other Income
34.30
17.00
101.76%
13.80
28.40
-51.41%
30.20
30.80
-1.95%
38.00
25.70
47.86%
Interest
4.20
2.00
110.00%
6.70
3.50
91.43%
5.00
3.40
47.06%
4.00
2.70
48.15%
Depreciation
39.60
33.80
17.16%
38.10
30.40
25.33%
36.00
29.80
20.81%
34.70
28.70
20.91%
PBT
385.80
91.00
323.96%
-49.60
70.70
-
91.00
80.10
13.61%
69.80
270.70
-74.21%
Tax
65.40
16.00
308.75%
0.90
17.70
-94.92%
10.60
16.70
-36.53%
4.70
66.80
-92.96%
PAT
320.40
75.00
327.20%
-50.50
53.00
-
80.40
63.40
26.81%
65.10
203.90
-68.07%
PATM
36.22%
18.28%
-8.46%
16.00%
14.34%
17.85%
17.26%
25.42%
EPS
17.56
4.11
327.25%
-2.77
2.90
-
4.41
3.45
27.83%
3.57
11.12
-67.90%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
2,419.10
1,944.80
2,052.10
1,915.00
2,094.50
2,184.80
2,020.20
1,141.30
825.28
738.89
660.53
Net Sales Growth
27.39%
-5.23%
7.16%
-8.57%
-4.13%
8.15%
77.01%
38.29%
11.69%
11.86%
 
Cost Of Goods Sold
629.50
528.40
483.70
354.40
332.70
411.10
599.10
341.10
242.37
233.23
242.80
Gross Profit
1,789.60
1,416.40
1,568.40
1,560.60
1,761.80
1,773.70
1,421.10
800.20
582.90
505.67
417.73
GP Margin
73.98%
72.83%
76.43%
81.49%
84.12%
81.18%
70.34%
70.11%
70.63%
68.44%
63.24%
Total Expenditure
1,870.10
1,681.30
1,448.30
1,332.40
1,299.70
1,256.40
1,336.80
868.70
611.90
559.56
510.60
Power & Fuel Cost
-
76.40
61.10
62.40
59.60
56.20
50.50
43.70
43.24
44.77
38.75
% Of Sales
-
3.93%
2.98%
3.26%
2.85%
2.57%
2.50%
3.83%
5.24%
6.06%
5.87%
Employee Cost
-
444.80
414.90
375.00
355.90
325.60
243.20
189.60
136.92
112.77
102.29
% Of Sales
-
22.87%
20.22%
19.58%
16.99%
14.90%
12.04%
16.61%
16.59%
15.26%
15.49%
Manufacturing Exp.
-
344.90
165.70
243.30
276.40
182.60
141.20
105.20
73.04
76.57
65.10
% Of Sales
-
17.73%
8.07%
12.70%
13.20%
8.36%
6.99%
9.22%
8.85%
10.36%
9.86%
General & Admin Exp.
-
161.50
242.90
132.60
126.40
105.50
88.10
73.40
63.66
56.21
39.49
% Of Sales
-
8.30%
11.84%
6.92%
6.03%
4.83%
4.36%
6.43%
7.71%
7.61%
5.98%
Selling & Distn. Exp.
-
43.70
34.40
98.10
90.00
136.90
143.20
91.60
37.36
26.16
14.82
% Of Sales
-
2.25%
1.68%
5.12%
4.30%
6.27%
7.09%
8.03%
4.53%
3.54%
2.24%
Miscellaneous Exp.
-
81.60
45.60
66.60
58.70
38.50
71.50
24.10
15.31
9.85
14.82
% Of Sales
-
4.20%
2.22%
3.48%
2.80%
1.76%
3.54%
2.11%
1.86%
1.33%
1.11%
EBITDA
549.00
263.50
603.80
582.60
794.80
928.40
683.40
272.60
213.38
179.33
149.93
EBITDA Margin
22.69%
13.55%
29.42%
30.42%
37.95%
42.49%
33.83%
23.89%
25.86%
24.27%
22.70%
Other Income
116.30
99.00
106.00
107.40
130.20
40.40
13.90
9.90
14.91
16.71
12.41
Interest
19.90
17.70
13.30
21.50
19.30
15.40
18.50
22.90
31.68
36.62
26.31
Depreciation
148.40
142.60
116.90
99.80
81.00
66.20
54.40
51.00
47.27
30.44
22.12
PBT
497.00
202.20
579.60
568.70
824.70
887.20
624.40
208.60
149.34
128.98
113.90
Tax
81.60
32.20
137.20
110.60
182.30
192.00
139.50
52.80
3.95
30.87
36.44
Tax Rate
16.42%
15.92%
23.67%
19.45%
22.11%
21.64%
22.34%
25.31%
2.94%
23.93%
35.61%
PAT
415.40
170.00
440.90
460.80
644.40
696.20
486.00
157.10
134.62
102.74
71.87
PAT before Minority Interest
415.40
170.00
442.40
458.10
642.40
695.20
484.90
155.80
130.27
98.11
65.88
Minority Interest
0.00
0.00
-1.50
2.70
2.00
1.00
1.10
1.30
4.35
4.63
5.99
PAT Margin
17.17%
8.74%
21.49%
24.06%
30.77%
31.87%
24.06%
13.77%
16.31%
13.90%
10.88%
PAT Growth
5.08%
-61.44%
-4.32%
-28.49%
-7.44%
43.25%
209.36%
16.70%
31.03%
42.95%
 
EPS
22.75
9.31
24.15
25.24
35.29
38.13
26.62
8.60
7.37
5.63
3.94

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
4,263.60
4,121.60
3,773.50
3,489.00
3,072.20
1,649.30
1,295.70
846.05
725.88
533.54
Share Capital
36.50
36.50
36.40
36.50
36.90
34.90
34.80
33.23
33.07
31.37
Total Reserves
4,223.70
4,067.60
3,713.60
3,421.70
3,011.40
1,599.00
1,251.20
812.82
692.80
502.17
Non-Current Liabilities
135.10
142.90
117.80
83.40
47.10
37.70
28.00
119.23
150.67
191.46
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
94.03
92.20
135.62
Unsecured Loans
0.00
0.00
0.90
0.00
0.00
0.00
0.00
2.99
3.28
2.21
Long Term Provisions
95.70
99.60
90.20
71.00
32.40
21.90
12.50
9.50
11.09
8.62
Current Liabilities
710.40
525.60
685.30
728.70
592.00
626.50
493.10
413.74
312.28
344.87
Trade Payables
161.80
146.20
255.40
217.00
269.10
262.70
275.60
125.30
109.79
105.85
Other Current Liabilities
126.70
99.50
95.90
109.80
133.40
127.10
114.20
118.56
102.18
90.21
Short Term Borrowings
404.00
265.80
315.00
386.30
173.20
221.60
98.40
168.54
98.63
147.74
Short Term Provisions
17.90
14.10
19.00
15.60
16.30
15.10
4.90
1.33
1.69
1.07
Total Liabilities
5,109.10
4,791.90
4,587.80
4,303.10
3,715.10
2,317.60
1,821.70
1,384.05
1,195.71
1,080.41
Net Block
2,311.80
2,023.20
1,584.40
1,227.20
1,018.60
833.00
710.10
709.97
644.74
582.75
Gross Block
3,126.90
2,702.10
2,148.70
1,694.50
1,407.60
1,158.70
983.30
939.98
819.89
726.97
Accumulated Depreciation
815.10
678.90
564.30
467.30
389.00
325.70
273.20
225.82
171.11
140.57
Non Current Assets
2,611.90
2,447.10
2,262.20
1,955.90
1,584.40
1,230.30
984.70
901.08
827.57
749.94
Capital Work in Progress
129.50
223.40
518.00
637.60
480.00
336.30
211.80
128.96
123.78
105.84
Non Current Investment
104.40
151.90
83.60
19.90
8.10
0.10
0.10
1.57
1.57
1.54
Long Term Loans & Adv.
61.50
44.30
72.00
62.80
75.40
60.40
62.10
57.03
54.25
57.20
Other Non Current Assets
4.70
4.30
4.20
8.40
2.30
0.50
0.60
3.54
3.24
2.61
Current Assets
2,497.20
2,344.80
2,325.60
2,347.20
2,130.70
1,087.30
837.00
482.97
368.14
330.48
Current Investments
203.70
151.80
28.70
148.70
68.40
32.10
22.10
0.12
0.32
0.81
Inventories
762.00
798.20
558.00
529.00
438.40
348.90
357.30
220.00
181.12
146.02
Sundry Debtors
620.60
412.90
551.30
506.20
637.50
475.20
261.60
192.43
118.80
129.71
Cash & Bank
206.10
283.50
66.00
279.50
183.70
35.80
45.20
13.36
11.05
10.78
Other Current Assets
704.80
94.70
91.60
107.40
802.70
195.30
150.80
57.06
56.85
43.14
Short Term Loans & Adv.
616.70
603.70
1,030.00
776.40
749.50
169.50
125.40
40.97
52.46
38.85
Net Current Assets
1,786.80
1,819.20
1,640.30
1,618.50
1,538.70
460.80
343.90
69.23
55.85
-14.39
Total Assets
5,109.10
4,791.90
4,587.80
4,303.10
3,715.10
2,317.60
1,821.70
1,384.05
1,195.71
1,080.42

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
46.50
298.80
417.30
668.80
463.60
345.80
112.20
92.67
144.03
61.19
PBT
202.20
579.60
568.70
824.70
887.20
624.40
208.60
134.22
128.98
102.32
Adjustment
123.90
62.10
54.00
14.30
75.60
100.20
90.50
68.14
65.72
48.87
Changes in Working Capital
-231.40
-212.90
-97.60
8.60
-294.60
-253.00
-140.70
-85.96
-16.11
-67.39
Cash after chg. in Working capital
94.70
428.80
525.10
847.60
668.20
471.60
158.40
116.41
178.58
83.80
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-48.20
-130.00
-107.80
-178.80
-204.60
-125.80
-46.20
-23.74
-34.55
-22.61
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-5.30
-103.30
-167.00
-612.20
-1,115.50
-299.40
-175.50
-114.75
-108.92
-107.07
Net Fixed Assets
-204.80
-250.20
-335.80
-436.10
-392.40
-299.40
-303.91
-100.13
-99.70
-102.47
Net Investments
-213.00
-145.90
53.30
-94.80
-54.80
-1.00
37.47
-42.37
-11.33
-2.67
Others
412.50
292.80
115.50
-81.30
-668.30
1.00
90.94
27.75
2.11
-1.93
Cash from Financing Activity
34.80
-185.70
-250.80
-50.90
650.90
-47.70
154.00
29.07
-35.27
26.31
Net Cash Inflow / Outflow
76.00
9.80
-0.50
5.70
-1.00
-1.30
90.70
6.99
-0.15
-19.57
Opening Cash & Equivalents
25.80
19.80
28.30
21.70
23.50
24.20
-164.10
10.22
9.95
34.64
Closing Cash & Equivalent
111.10
25.80
19.80
28.30
21.70
23.50
-74.20
12.44
10.22
9.95

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
233.44
224.88
206.04
189.49
165.22
93.63
73.91
50.91
219.48
170.06
ROA
3.43%
9.43%
10.30%
16.02%
23.05%
23.43%
9.72%
10.10%
8.62%
6.64%
ROE
4.06%
11.27%
12.71%
19.75%
29.70%
33.21%
14.62%
16.57%
15.58%
13.08%
ROCE
4.86%
13.99%
14.82%
23.71%
35.28%
39.21%
18.04%
15.62%
18.02%
16.04%
Fixed Asset Turnover
0.76
0.86
1.07
1.47
1.72
1.93
1.23
0.95
0.96
1.14
Receivable days
85.10
84.44
93.77
91.36
92.22
65.12
70.27
67.76
60.90
61.30
Inventory Days
128.47
118.77
96.38
77.28
65.25
62.41
89.35
87.33
80.17
70.04
Payable days
106.38
151.52
65.96
72.53
81.42
78.30
85.42
73.36
74.09
73.36
Cash Conversion Cycle
107.20
51.68
124.19
96.11
76.05
49.23
74.21
81.73
66.99
57.98
Total Debt/Equity
0.09
0.06
0.08
0.11
0.06
0.14
0.09
0.37
0.33
0.63
Interest Cover
12.42
44.58
27.45
43.73
58.61
34.75
10.11
5.24
4.52
4.89

Annual Reports:

FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013

News Update:


  • Natco Pharma launches Chlorantraniliprole combination Agro Products in India
    4th Oct 2022, 11:30 AM

    Syngenta markets these combination products under brand names Voliam Flexi and Ampligo

    Read More
  • Natco Pharma launches Chlorantraniliprole 18.5% SC under Brand Name 'NATGEN'
    26th Sep 2022, 09:09 AM

    The company estimates the current market size of CTPR containing products in India to be over Rs 2000 crore.

    Read More
  • Natco Pharma gets CTPR launch approval from Delhi High Court
    20th Sep 2022, 09:58 AM

    CTPR technical is formulated into broad-spectrum insecticides used across wide range of crops for pest management

    Read More
  • Natco Pharma gets nod to sell stake in Nativita
    3rd Sep 2022, 11:02 AM

    The Board of Directors of the Company at their meeting held on September 02, 2022 have considered and approved the same

    Read More
  • Natco Pharma gets USFDA’s tentative approval for Trabectedin for Injection
    18th Aug 2022, 09:09 AM

    Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market

    Read More
  • Natco Pharma - Quarterly Results
    9th Aug 2022, 14:01 PM

    Read More
  • Natco Pharma gets approval for its partner’s ANDA for Cabazitaxel Intravenous Solution
    25th Jul 2022, 10:45 AM

    According to industry sales data, Jevtana Kit generated annual sales of $303 million during the twelve months ending May 2022

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.